BBS4 (BBSome complex member BBS4) variants and mutations
BBS4 (also known as BBSome complex member BBS4) is a human protein-coding gene encoding a BBSome complex member protein. It helps assemble and localize the BBSome and links ciliary trafficking machinery to the cytoskeleton. Biallelic pathogenic variants cause Bardet-Biedl syndrome, with characteristic retinal, metabolic, renal, and developmental manifestations. This analysis covers 772 BBS4 variants and mutations. Of these, 76% have computational variant effect predictions. Disease context includes Bardet-Biedl syndrome 4, Bardet-Biedl syndrome, and Bardet-Biedl syndrome 1. Example BBS4 variants include M1T, M1V, and A2G.
Variant analysis overview
- Gene: BBS4
- Protein: BBSome complex member BBS4
- UniProt accession: Q96RK4
- Organism: Homo sapiens
- Variants analyzed: 772
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 695 unspecified-consequence records; 45 missense variants; 15 synonymous variants; 3 in-frame deletions; 3 stop-gained variants; 2 splice-region variants; 6 frameshift variants; 3 substitution
- Prediction scores: 589 variants have prediction scores (76% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Bardet-Biedl syndrome 4, Bardet-Biedl syndrome, Bardet-Biedl syndrome 1, retinitis pigmentosa, polydactyly, obesity disorder, obesity due to melanocortin 4 receptor deficiency, Obesity, eye disorder, Retinal dystrophy, response to statin, Tinnitus.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable BBS4 variants
Examples include M1T, M1V, A2G, A2V, A2P, A2T, A2S, A2D. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs1302879683, ClinGen CA393074972, ClinVar RCV000514162, ClinVar RCV002524988, MutPred 0.99, Pathogenic/Likely pathogenic, Bardet-Biedl syndrome 4; Bardet-Biedl syndrome; not provided
- M1V (p.Met1Val), rs773109542, ClinGen CA7646416, ClinVar RCV002556528, ClinVar RCV004749606, MutPred 0.99, Uncertain significance, Bardet-Biedl syndrome; Bardet-Biedl syndrome 4
- A2G (p.Ala2Gly), TOPMed rs923399180, gnomAD rs923399180, REVEL 0.37, MetaLR 0.47, Uncertain significance
- A2V (p.Ala2Val), rs923399180, ClinGen CA272613050, ClinVar RCV001883248, TOPMed rs923399180, REVEL 0.42, MetaLR 0.47, Uncertain significance, Bardet-Biedl syndrome
- A2P (p.Ala2Pro), gnomAD 15-72686231-G-C, REVEL 0.40, MetaLR 0.48
- A2T (p.Ala2Thr), gnomAD 15-72686231-G-A, REVEL 0.37, MetaLR 0.48
- A2S (p.Ala2Ser), gnomAD 15-72686231-G-T, REVEL 0.34, MetaLR 0.47
- A2D (p.Ala2Asp), gnomAD 15-72686232-C-A, REVEL 0.37, MetaLR 0.45
- A2A (p.Ala2Ala), rs954863260, gnomAD 15-72686233-T-C, CADD 6.74
- E3A (p.Glu3Ala), rs113994183, ClinGen CA342437, ClinVar RCV000020946, Ensembl rs113994183, MutPred 0.24, Benign, Bardet-Biedl syndrome
- E3* (p.Glu3Ter), gnomAD 15-72686234-G-T, CADD 44.00
- E3K (p.Glu3Lys), gnomAD 15-72686234-G-A, REVEL 0.31, MetaLR 0.41
- E3V (p.Glu3Val), gnomAD 15-72686235-A-T, REVEL 0.34, MetaLR 0.42
- E3D (p.Glu3Asp), gnomAD 15-72686236-G-T, REVEL 0.32, MetaLR 0.28
- E3E (p.Glu3Glu), rs1313222448, gnomAD 15-72686236-G-A, CADD 6.32
- E4* (p.Glu4Ter), rs1336636537, ClinGen CA393075014, ClinVar RCV002624712, ClinVar RCV003459766, CADD 50.00, Pathogenic
- E4G (p.Glu4Gly), ExAC rs760505590, TOPMed rs760505590, gnomAD rs760505590, REVEL 0.21, MetaLR 0.23
- E4K (p.Glu4Lys), rs1336636537, ClinGen CA393075010, ClinVar RCV001914494, gnomAD rs1336636537, REVEL 0.25, MetaLR 0.21, Uncertain significance, Bardet-Biedl syndrome
- E4Q (p.Glu4Gln), rs1336636537, ClinGen CA393075012, ClinVar RCV002838977, MutPred 0.32, Uncertain significance, Bardet-Biedl syndrome
- E4del (p.Glu4del), gnomAD 15-72686233-TGAG-, CADD 20.10
- E4V (p.Glu4Val), gnomAD 15-72686238-A-T, REVEL 0.23, MetaLR 0.23
- E4E (p.Glu4Glu), rs543735239, gnomAD 15-72686239-G-A, CADD 6.52
- E4D (p.Glu4Asp), gnomAD 15-72686239-G-T, REVEL 0.24, MetaLR 0.21
- R5* (p.Arg5Ter), TOPMed rs1293905470, gnomAD rs1293905470, CADD 36.00
- R5G (p.Arg5Gly), NCI-TCGA Cosmic COSV9916, TOPMed rs1293905470, gnomAD rs1293905470, REVEL 0.27, MetaLR 0.17, Variant assessed as somatic; moderate impact.
- R5S (p.Arg5Ser), Ensembl rs1567389551, REVEL 0.25, MetaLR 0.12
- R5T (p.Arg5Thr), rs1307094685, ClinGen CA393075035, ClinVar RCV001929620, gnomAD rs1307094685, REVEL 0.14, MetaLR 0.10, Uncertain significance, Bardet-Biedl syndrome
- R5K (p.Arg5Lys), gnomAD 15-72686241-G-A, REVEL 0.11, MetaLR 0.07
- R5I (p.Arg5Ile), gnomAD 15-72686241-G-T, REVEL 0.30, MetaLR 0.14
- R5R (p.Arg5Arg), gnomAD 15-72686242-A-G, CADD 13.80
- V6A (p.Val6Ala), rs113994185, ClinGen CA342428, ClinVar RCV000020940, gnomAD rs113994185, REVEL 0.17, MetaLR 0.13, Benign, Bardet-Biedl syndrome
- V6F (p.Val6Phe), gnomAD rs1234241975, REVEL 0.19, MetaLR 0.18
- V6I (p.Val6Ile), rs1234241975, ClinGen CA393075042, ClinVar RCV003030492, REVEL 0.08, MetaLR 0.17, Uncertain significance, Bardet-Biedl syndrome
- V6D (p.Val6Asp), gnomAD 15-72686244-T-A, REVEL 0.27, MetaLR 0.15
- V6G (p.Val6Gly), gnomAD 15-72686244-T-G, REVEL 0.20, MetaLR 0.15
- V6V (p.Val6Val), rs113994187, gnomAD 15-72686245-C-T, CADD 2.82
- A7E (p.Ala7Glu), TOPMed rs113994186, gnomAD rs113994186, REVEL 0.12, MetaLR 0.13, Benign
- A7G (p.Ala7Gly), rs113994186, ClinGen CA393075064, ClinVar RCV002975856, REVEL 0.12, MetaLR 0.10, Uncertain significance, Bardet-Biedl syndrome
- A7P (p.Ala7Pro), rs2064831111, ClinGen CA393075057, ClinVar RCV001374258, Ensembl rs2064831111, REVEL 0.21, MetaLR 0.19, Uncertain significance, Bardet-Biedl syndrome
- A7T (p.Ala7Thr), rs2064831111, ClinGen CA393075059, ClinVar RCV002007742, Ensembl rs2064831111, REVEL 0.12, MetaLR 0.18, Uncertain significance, Bardet-Biedl syndrome
- A7V (p.Ala7Val), rs113994186, ClinGen CA342432, ClinVar RCV000020942, ClinVar RCV004748537, REVEL 0.16, MetaLR 0.14, Conflicting interpretations, BBS4-related disorder; Bardet-Biedl syndrome
- A7S (p.Ala7Ser), gnomAD 15-72686246-G-T, REVEL 0.16, MetaLR 0.14
- A7A (p.Ala7Ala), gnomAD 15-72686248-G-T, CADD 7.73
- T8M (p.Thr8Met), rs769894375, ClinGen CA7646419, ClinVar RCV001905246, ClinVar RCV004749753, REVEL 0.09, MetaLR 0.15, Uncertain significance, Bardet-Biedl syndrome
- T8R (p.Thr8Arg), ExAC rs769894375, TOPMed rs769894375, gnomAD rs769894375, REVEL 0.10, MetaLR 0.17, Uncertain significance
- T8S (p.Thr8Ser), TOPMed rs2064831225, Uncertain significance, Inborn genetic diseases
- T8A (p.Thr8Ala), gnomAD 15-72686249-A-G, REVEL 0.19, MetaLR 0.10
- T8K (p.Thr8Lys), gnomAD 15-72686250-C-A, REVEL 0.12, MetaLR 0.16
- T8T (p.Thr8Thr), gnomAD 15-72686251-G-A, CADD 32.00
- T8I (p.Thr8Ile), gnomAD 15-72686527-C-T, CADD 2.86, SIFT 0.06
- R9I (p.Arg9Ile), NCI-TCGA Cosmic COSV5143, Variant assessed as somatic; moderate impact.
- R9S (p.Arg9Ser), ESP rs371162394, ExAC rs371162394, gnomAD rs371162394
- T10A (p.Thr10Ala), gnomAD 15-72695180-A-G, REVEL 0.36, MetaLR 0.19
- Q11* (p.Gln11Ter), rs1040144478, ClinGen CA393075497, ClinVar RCV003465091, ClinVar RCV003633724, MutPred 0.15, Pathogenic
- Q11E (p.Gln11Glu), rs1040144478, ClinGen CA393075498, ClinVar RCV001895571, TOPMed rs1040144478, REVEL 0.29, MetaLR 0.19, Uncertain significance, Bardet-Biedl syndrome
- Q11K (p.Gln11Lys), TOPMed rs1040144478, gnomAD rs1040144478, Uncertain significance
- Q11R (p.Gln11Arg), gnomAD rs1428455125, REVEL 0.29, MetaLR 0.19
- F12L (p.Phe12Leu), rs1454701575, gnomAD 15-72686541-T-C, CADD 6.57, SIFT 0.90
- P13S (p.Pro13Ser), rs151164191, ClinGen CA7646456, ClinVar RCV000400282, ClinVar RCV001094446, REVEL 0.13, MetaLR 0.22, Conflicting interpretations, Bardet-Biedl syndrome; Bardet-Biedl syndrome 4
- P13H (p.Pro13His), gnomAD 15-72695190-C-A, REVEL 0.32, MetaLR 0.29
- P13P (p.Pro13Pro), rs990984115, gnomAD 15-72695191-T-G, CADD 7.60
- V14A (p.Val14Ala), Ensembl rs764379682
- V14I (p.Val14Ile), 1000Genomes rs542595190, ExAC rs542595190, gnomAD rs542595190, CADD 9.37, SIFT 0.22
- V14C (p.Val14Cys), gnomAD 15-72686544-T-TC, CADD 2.74
- V14L (p.Val14Leu), gnomAD 15-72686547-G-C, CADD 0.85, SIFT 0.16
- V14D (p.Val14Asp), gnomAD 15-72686557-T-A, CADD 11.40, SIFT 0.59
- V14V (p.Val14Val), rs113994181, gnomAD 15-72695194-A-G, CADD 3.00
- S15A (p.Ser15Ala), Ensembl rs1595906911
- S15C (p.Ser15Cys), NCI-TCGA Cosmic COSV9916, Variant assessed as somatic; moderate impact.
- S15Y (p.Ser15Tyr), TOPMed rs2065053817, REVEL 0.35, MetaLR 0.26
- S15P (p.Ser15Pro), gnomAD 15-72686544-T-C, CADD 5.79, SIFT 0.27
- S15W (p.Ser15Trp), rs1595897380, gnomAD 15-72686551-C-G, CADD 0.53, SIFT 0.06
- S15L (p.Ser15Leu), rs1595897380, gnomAD 15-72686551-C-T, CADD 0.66, SIFT 0.25
- S15* (p.Ser15Ter), gnomAD 15-72686551-C-A, CADD 0.49
- S15F (p.Ser15Phe), gnomAD 15-72695196-C-T, REVEL 0.36, MetaLR 0.27
- S15S (p.Ser15Ser), rs2065053978, gnomAD 15-72695197-T-C, CADD 7.74
- T16A (p.Thr16Ala), Ensembl rs929043364, REVEL 0.08, MetaLR 0.12
- T16I (p.Thr16Ile), TOPMed rs1327916676, gnomAD rs1327916676
- T16S (p.Thr16Ser), TOPMed rs1327916676, gnomAD rs1327916676, REVEL 0.11, MetaLR 0.13
- T16del (p.Thr16del), rs1260734059, gnomAD 15-72695195-TCTA-, CADD 16.40
- T16N (p.Thr16Asn), gnomAD 15-72695199-C-A, REVEL 0.07, MetaLR 0.18
- E17K (p.Glu17Lys), gnomAD 15-72695201-G-A, REVEL 0.27, MetaLR 0.20
- E17Q (p.Glu17Gln), gnomAD 15-72695201-G-C, REVEL 0.24, MetaLR 0.22
- S18F (p.Ser18Phe), Ensembl rs2150997273, REVEL 0.24, MetaLR 0.22
- S18P (p.Ser18Pro), gnomAD 15-72695204-T-C, REVEL 0.14, MetaLR 0.14
- S18S (p.Ser18Ser), rs1323367957, gnomAD 15-72695206-T-C, CADD 8.53
- Q19* (p.Gln19Ter), rs2542892124, ClinGen CA393075548, ClinVar RCV003465078, ClinVar RCV003523201, Pathogenic
- Q19P (p.Gln19Pro), ExAC rs768719848, gnomAD rs768719848, REVEL 0.33, MetaLR 0.18
- Q19E (p.Gln19Glu), gnomAD 15-72695207-C-G, REVEL 0.13, MetaLR 0.22
- Q19K (p.Gln19Lys), gnomAD 15-72695207-C-A, REVEL 0.21, MetaLR 0.16
- Q19R (p.Gln19Arg), gnomAD 15-72695208-A-G, REVEL 0.17, MetaLR 0.12
- Q19Q (p.Gln19Gln), gnomAD 15-72695209-A-G, CADD 0.54
- K20* (p.Lys20Ter), TOPMed rs2065054289
- K20I (p.Lys20Ile), NCI-TCGA Cosmic COSV5143, Variant assessed as somatic; moderate impact.
- K20E (p.Lys20Glu), gnomAD 15-72686562-A-G, CADD 8.40, SIFT 0.69
- K20N (p.Lys20Asn), gnomAD 15-72695207-CA-C, CADD 22.80
- K20Q (p.Lys20Gln), gnomAD 15-72695210-A-C, REVEL 0.13, MetaLR 0.09
- K20R (p.Lys20Arg), gnomAD 15-72695211-A-G, REVEL 0.18, MetaLR 0.10
- K20K (p.Lys20Lys), rs1567398780, gnomAD 15-72695212-A-G, CADD 4.89
- P21S (p.Pro21Ser), rs916749492, ClinGen CA272620932, ClinVar RCV001340067, TOPMed rs916749492, REVEL 0.06, MetaLR 0.06, Uncertain significance, Inborn genetic diseases; Bardet-Biedl syndrome
- p.Pro21 Arg22del, gnomAD 15-72695212-ACCCC, CADD 12.50
- P21R (p.Pro21Arg), rs1595906940, gnomAD 15-72695212-ACCCC, CADD 23.30
- P21T (p.Pro21Thr), gnomAD 15-72695213-C-A, REVEL 0.04, MetaLR 0.10
- P21H (p.Pro21His), gnomAD 15-72695214-C-A, REVEL 0.08, MetaLR 0.12
- P21P (p.Pro21Pro), rs267604309, gnomAD 15-72695215-C-T, CADD 0.44
- R22G (p.Arg22Gly), ExAC rs727503820, TOPMed rs727503820, gnomAD rs727503820, REVEL 0.08, MetaLR 0.11, Uncertain significance
- R22L (p.Arg22Leu), ExAC rs775955872, TOPMed rs775955872, gnomAD rs775955872, Uncertain significance
- R22Q (p.Arg22Gln), rs775955872, ClinGen CA7646460, ClinVar RCV001316446, ClinVar RCV002504488, REVEL 0.01, MetaLR 0.08, Uncertain significance, Bardet-Biedl syndrome 4; Bardet-Biedl syndrome
- R22W (p.Arg22Trp), rs727503820, ClinGen CA233515, ClinVar RCV000152837, ClinVar RCV001246608, REVEL 0.09, MetaLR 0.13, Uncertain significance, not provided; Bardet-Biedl syndrome; Bardet-Biedl syndrome 4
- R22R (p.Arg22Arg), gnomAD 15-72695216-C-A, CADD 5.95
- Q23* (p.Gln23Ter), rs2542892241, ClinGen CA393075570, ClinVar RCV002740200, ClinVar RCV004571215, CADD 34.00, Pathogenic
- Q23K (p.Gln23Lys), gnomAD 15-72695219-C-A, REVEL 0.10, MetaLR 0.05
- Q23Q (p.Gln23Gln), rs1481552507, gnomAD 15-72695221-G-A, CADD 0.90
- Q23H (p.Gln23His), gnomAD 15-72695221-G-T, REVEL 0.04, MetaLR 0.06
- K24Q (p.Lys24Gln), gnomAD rs1488320107, REVEL 0.20, MetaLR 0.10
- K24R (p.Lys24Arg), ExAC rs750642149, TOPMed rs750642149, gnomAD rs750642149, REVEL 0.25, MetaLR 0.10
- K25R (p.Lys25Arg), gnomAD 15-72695226-A-G, REVEL 0.27, MetaLR 0.11
- K25K (p.Lys25Lys), rs761050940, gnomAD 15-72695227-A-G, CADD 22.20
- K25N (p.Lys25Asn), gnomAD 15-72695227-A-T, REVEL 0.13, MetaLR 0.16
- A26V (p.Ala26Val), rs2151016128, ClinGen CA393075745, ClinVar RCV001892434, Ensembl rs2151016128, REVEL 0.23, MetaLR 0.13, Uncertain significance, Bardet-Biedl syndrome
- A26E (p.Ala26Glu), rs1269839098, gnomAD 15-72695219-C-CAA, CADD 17.20
- A26L (p.Ala26Leu), gnomAD 15-72695221-GA-G, CADD 24.10
- A26S (p.Ala26Ser), rs1567398832, gnomAD 15-72695221-G-GA, CADD 23.90
- A26T (p.Ala26Thr), gnomAD 15-72695228-G-A, REVEL 0.24, MetaLR 0.19
- P27L (p.Pro27Leu), rs748048479, ClinGen CA7646496, NCI-TCGA Cosmic COSV9916, ClinVar RCV001213528, REVEL 0.20, MetaLR 0.14, Uncertain significance, Bardet-Biedl syndrome
- E28A (p.Glu28Ala), Ensembl rs1567410420, REVEL 0.29, MetaLR 0.30
- E28D (p.Glu28Asp), NCI-TCGA Cosmic COSV9916, ExAC rs772122336, TOPMed rs772122336, gnomAD rs772122336, Likely benign
- E28G (p.Glu28Gly), Ensembl rs1567410420, REVEL 0.37, MetaLR 0.35
- F29V (p.Phe29Val), rs1343702152, ClinGen CA393075764, ClinVar RCV002301557, gnomAD rs1343702152, REVEL 0.11, MetaLR 0.09, Uncertain significance, Bardet-Biedl syndrome
- P30S (p.Pro30Ser), NCI-TCGA Cosmic COSV5144, Variant assessed as somatic; moderate impact.
- I31V (p.Ile31Val), rs113994182, ClinGen CA342439, ClinVar RCV000020947, ExAC rs113994182, REVEL 0.08, MetaLR 0.09, Benign, Bardet-Biedl syndrome
- L32* (p.Leu32Ter), rs2542931853, ClinGen CA393075784, ClinVar RCV003465085, Likely pathogenic
- L32F (p.Leu32Phe), rs775255819, gnomAD 15-72686523-C-T, CADD 3.93, SIFT 0.04
- L32V (p.Leu32Val), rs775255819, gnomAD 15-72686523-C-G, CADD 3.43, SIFT 1.00
- E33G (p.Glu33Gly), 1000Genomes rs141156155, ExAC rs141156155, gnomAD rs141156155, REVEL 0.60, MetaLR 0.35
- E33* (p.Glu33Ter), gnomAD 15-72695228-G-T, REVEL 0.18, MetaLR 0.19
- Q35* (p.Gln35Ter), rs2542931886, ClinGen CA393075806, ClinVar RCV003465092, CADD 36.00, SIFT 0.00, Likely pathogenic
- Q35H (p.Gln35His), NCI-TCGA TCGA novel, REVEL 0.08, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- W37* (p.Trp37Ter), rs370049399, ClinGen CA272633130, ClinVar RCV003911439, ESP rs370049399, CADD 39.00, Likely pathogenic
- W37C (p.Trp37Cys), ExAC rs765714902, gnomAD rs765714902, REVEL 0.54, MetaLR 0.39
- W37L (p.Trp37Leu), ESP rs370049399, TOPMed rs370049399, gnomAD rs370049399, Likely pathogenic
- I39T (p.Ile39Thr), rs2542931922, ClinGen CA393075838, ClinVar RCV002811027, REVEL 0.43, MetaLR 0.35, Uncertain significance, Bardet-Biedl syndrome
- H40R (p.His40Arg), TOPMed rs1190175927, gnomAD rs1190175927, REVEL 0.59, MetaLR 0.35
- L41F (p.Leu41Phe), TOPMed rs2065331386
- H42R (p.His42Arg), ExAC rs767043854, gnomAD rs767043854, REVEL 0.15, MetaLR 0.12
- H42Y (p.His42Tyr), rs2542931978, ClinGen CA393075856, ClinVar RCV002849672, Uncertain significance, Inborn genetic diseases
- Y43* (p.Tyr43Ter), rs2065331681, ClinGen CA393075869, ClinVar RCV001199436, Ensembl rs2065331681, Pathogenic
- Y43C (p.Tyr43Cys), gnomAD rs1157159655, REVEL 0.56, MetaLR 0.34
- I44T (p.Ile44Thr), gnomAD rs1360298049, REVEL 0.19, MetaLR 0.10
- I44V (p.Ile44Val), rs749951346, ClinGen CA7646506, ClinVar RCV003305073, ExAC rs749951346, REVEL 0.03, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- R45Q (p.Arg45Gln), rs1050164962, ClinGen CA272633189, NCI-TCGA Cosmic COSV5143, ClinVar RCV001051434, REVEL 0.11, MetaLR 0.11, Uncertain significance, Bardet-Biedl syndrome; Bardet-Biedl syndrome 4
- R45W (p.Arg45Trp), rs760345612, ClinGen CA7646507, ClinVar RCV002695346, ClinVar RCV004749947, REVEL 0.30, MetaLR 0.34, Uncertain significance, Bardet-Biedl syndrome 4; Bardet-Biedl syndrome; Inborn genetic diseases
- K46E (p.Lys46Glu), Ensembl rs927016220
- K46R (p.Lys46Arg), rs75295839, ClinGen CA202441, ClinVar RCV000177393, ClinVar RCV000425800, REVEL 0.12, MetaLR 0.11, Conflicting interpretations, not specified; not provided; Bardet-Biedl syndrome
- K46T (p.Lys46Thr), 1000Genomes rs75295839, ESP rs75295839, ExAC rs75295839, TOPMed rs75295839, REVEL 0.31, MetaLR 0.34, Benign
- D47E (p.Asp47Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D47G (p.Asp47Gly), Ensembl rs2065332116
- D47H (p.Asp47His), gnomAD rs1435823640, REVEL 0.45, MetaLR 0.32
- Y48D (p.Tyr48Asp), gnomAD rs1373920809, REVEL 0.68, MetaLR 0.44, Uncertain significance, BBS4-related disorder
- E49A (p.Glu49Ala), rs1306734630, ClinGen CA393075904, ClinVar RCV002768092, MutPred 0.34, Uncertain significance, Inborn genetic diseases
- E49G (p.Glu49Gly), gnomAD rs1306734630, REVEL 0.17, MetaLR 0.10
- A50D (p.Ala50Asp), gnomAD rs1352701769, REVEL 0.16, MetaLR 0.11
- A50G (p.Ala50Gly), gnomAD rs1352701769, REVEL 0.09, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- A50T (p.Ala50Thr), TOPMed rs1210338376
- A50V (p.Ala50Val), gnomAD rs1352701769, REVEL 0.08, MetaLR 0.12
- C51Y (p.Cys51Tyr), TOPMed rs1008706809, gnomAD rs1008706809, REVEL 0.68, MetaLR 0.39
- A53D (p.Ala53Asp), ExAC rs750645085, TOPMed rs750645085, gnomAD rs750645085, REVEL 0.09, MetaLR 0.19
- A53V (p.Ala53Val), ExAC rs750645085, TOPMed rs750645085, gnomAD rs750645085, REVEL 0.05, MetaLR 0.14
- V54I (p.Val54Ile), TOPMed rs943785660
- I55M (p.Ile55Met), NCI-TCGA Cosmic COSV5143, Variant assessed as somatic; moderate impact.
- I55N (p.Ile55Asn), TOPMed rs1423288906, gnomAD rs1423288906, REVEL 0.50, MetaLR 0.35
- I55T (p.Ile55Thr), TOPMed rs1423288906, gnomAD rs1423288906, REVEL 0.47, MetaLR 0.34
- K56I (p.Lys56Ile), TOPMed rs1422003622, gnomAD rs1422003622, REVEL 0.31, MetaLR 0.31
- E57K (p.Glu57Lys), ExAC rs758321666, TOPMed rs758321666, gnomAD rs758321666, REVEL 0.23, MetaLR 0.22, Uncertain significance, Bardet-Biedl syndrome 4
- Q58* (p.Gln58Ter), rs886039802, ClinGen CA10588975, ClinVar RCV000256420, ClinVar RCV003463722, Pathogenic
- Q58X, rs886039802, Pathogenic
- L59F (p.Leu59Phe), gnomAD rs1399403313, REVEL 0.27, MetaLR 0.40
- L59R (p.Leu59Arg), ExAC rs777527843, gnomAD rs777527843
- Q60R (p.Gln60Arg), rs916245903, ClinGen CA272635105, ClinVar RCV002043742, TOPMed rs916245903, REVEL 0.26, MetaLR 0.24, Uncertain significance, Bardet-Biedl syndrome
- E61K (p.Glu61Lys), rs1251827333, ClinGen CA393076066, ClinVar RCV001494740, UniProt VAR 066287, REVEL 0.38, MetaLR 0.26, Likely benign, Bardet-Biedl syndrome
Public BBS4 analysis runs
- BBS4 analysis run — BBS4 (772 variants) — completed 2026-08-22